Idiopathic inflammatory myopathy: Autoantibody update

Current Rheumatology Reports

Volumn 4, Issue 5, 2002, Pages 434-441

  Targoff, Ira N ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Dermatomyositis; Idiopathic Pulmonary Fibrosis; Inclusion Body Myositis; Interstitial Lung Disease; Myositis

Indexed keywords

AMINO ACID TRANSFER RNA LIGASE; AUTOANTIBODY; MI 2 ANTIBODIES; MI-2 ANTIBODIES;

ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; DERMATOMYOSITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOLOGY; POLYMYOSITIS; REVIEW;

AMINO ACYL-TRNA SYNTHETASES; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; AUTOANTIBODIES; DERMATOMYOSITIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; POLYMYOSITIS;

EID: 0036777060     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-002-0089-7     Document Type: Article

References (70)

1. Love LA, Leff RL, Fraser DD, et al.: A new approach to the classification of idiopathic inflammatory myopathy: myositisspecific autoantibodies define useful homogeneous patient groups. Medicine 1991, 70:360–374.
2. Miller FW, Twitty SA, Biswas T, Plotz PH: Origin and regulation of a disease-specific autoantibody response: antigenic epitopes, spectrotype stability, and isotype restriction of anti- Jo-1 antibodies. J Clin Invest 1990, 85:468–475.
3. Miller FW, Waite KA, Biswas T, Plotz PH: The role of an autoantigen, histidyl-tRNA synthetase, in the induction and maintenance of autoimmunity. Proc Natl Acad Sci U S A 1990, 87:9933–9937.
4. Targoff IN, Trieu EP, Plotz PH, Miller FW: Antibodies to glycyltransfer RNA synthetase in patients with myositis and interstitial lung disease. Arthritis Rheum 1992, 35:821–830.
5. Arnett FC, Targoff IN, Mimori T, et al.: Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis. Arthritis Rheum 1996, 39:1507–1518.
6. Targoff IN: Immune manifestations of inflammatory muscle disease. Rheum Dis Clin North Am 1994, 20:857–880.
7. Targoff IN: Autoantibodies and muscle disease. In Diseases of Skeletal Muscle. Edited by Wortmann RL. Philadelphia: Lippincott Williams & Wilkins; 2000:267–291.
8. Gelpi C, Kanterewicz E, Gratacos J, et al.: Coexistence of two antisynthetases in a patient with the antisynthetase syndrome. Arthritis Rheum 1996, 39:692–697.
9. Targoff IN, Johnson AE, Miller FW: Antibody to signal recognition particle in polymyositis. Arthritis Rheum 1990, 33:1361–1370.
10. Mierau R, Dick T, Bartz-Bazzanella P, et al.: Strong association of dermatomyositis-specific Mi-2 autoantibodies with a tryptophan at position 9 of the HLA-DR beta chain. Arthritis Rheum 1996, 39:868–876.
11. Oddis CV, Okano Y, Rudert WA, et al.: Serum autoantibody to the nucleolar antigen PM-Scl: clinical and immunogenetic associations. Arthritis Rheum 1992, 35:1211–1217.
12. Rutjes SA, Vree Egberts WT, Jongen P, et al.: Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin Exp Immunol 1997, 109:32–40.
13. Hausmanowa-Petrusewicz I, Kowalska-Oledzka E, Miller FW, et al.: Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997, 40:1257–1266.
14. Brouwer R, Hengstman GJ, Vree E, et al.: Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001, 60:116–123. This important multicenter study examined the frequency of myositis autoantibodies in a large number of European patients with myositis using sensitive techniques. Although trends were similar to previous studies, the study found a higher frequency of defined antibodies in inclusion body mysositis, of anti-Mi-2 in polymyositis, of anti-SRP in dermatomyositis, and of co-existence of myositis-associated autoantibodies, than previous studies.
15. Koffman BM, Rugiero M, Dalakas MC: Immune-mediated conditions and antibodies associated with sporadic inclusion body myositis. Muscle Nerve 1998, 21:115–117.
16. Mierau R, Dick T, Genth E: Less specific myositis autoantibodies? Ann Rheum Dis 2001, 60:810.
17. Marguerie C, Bunn CC, Beynon HLC, et al.: Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med 1990, 77:1019–1038.
18. Hengstman GJ, ter Laak HJ, van Engelen BG, van Venrooij BG: Anti-Jo-1 positive inclusion body myositis with a marked and sustained clinical improvement after oral prednisone. J Neurol Neurosurg Psychiatry 2001, 70:706. An interesting case that provides insight into the potential significance of anti-Jo-1 occurring in patients with inclusion body mysositis.
19. Vazquez-Abad D, Rothfield NF: Sensitivity and specificity of anti-Jo-1 antibodies in autoimmune diseases with myositis. Arthritis Rheum 1996, 39:292–296.
20. Hirakata M, Suwa A, Satoh S, et al.: Clinical features of Japanese patients with anti-aminoacyl tRNA synthetase autoantibodies: the immunogenetic backgrounds [abstract]. Arthritis Rheum 2000, 43:S378.
21. Targoff IN, Arnett FC: Clinical manifestations in patients with antibody to PL-12 antigen (alanyl-tRNA synthetase). Am J Med 1990, 88:241–251.
22. Friedman AW, Targoff IN, Arnett FC: Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum 1996, 26:459–467.
23. Hirakata M, Suwa A, Nagai S, et al.: Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease. J Immunol 1999, 162:2315–2320. This report describes the most recently identified anti-synthetase. The antibody immunoprecipitates a distinctive tranfer-ribonucleic-acid and specifically inhibits the function of the enzyme. It was found in association with lung disease but not myositis.
24. Hirakata M, Nagai S: Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol 2000, 12:501–508.
25. Marie I, Hatron PY, Hachulla E, et al.: Pulmonary involvement in polymyositis and in dermatomyositis. J Rheumatol 1998, 25:1336–1343.
26. Clawson K, Oddis CV: Adult respiratory distress syndrome in polymyositis patients with the anti-Jo-1 antibody. Arthritis Rheum 1995, 38:1519–1523.
27. Tomsic M, Sifrer F: Acute respiratory distress syndrome in a polymyositis patient with the anti-Jo-1 antibody. Wiener Klinische Wochenschrift 2000, 112:728–731.
28. Douglas WW, Tazelaar HD, Hartman TE, et al.: Polymyositisdermatomyositis- associated interstitial lung disease. Am J Respir Crit Care Med 2001, 164:1182–1185. Reviewing The Mayo Clinic experience with this condition, this study suggests that the majority of patients with interstitial lung disease in myositis have non-specific interstitial pneumonia and a better prognosis than idiopathic pulmonary fibrosis.
29. Kalenian M, Zweiman B: Inflammatory myopathy, bronchiolitis obliterans/organizing pneumonia, and anti-Jo-1 antibodies: an interesting association. Clin Diagn Lab Immunol 1997, 4:236–240.
30. Oddis CV, Medsger TA Jr, Cooperstein LA: A subluxing arthropathy associated with the anti-Jo-1 antibody in polymyositis/ dermatomyositis. Arthritis Rheum 1990, 33:1640–1645.
31. Schmidt WA, Wetzel W, Friedlander R, et al.: Clinical and serological aspects of patients with anti-Jo-1 antibodies: an evolving spectrum of disease manifestations. Clin Rheumatol 2000, 19:371–377. This extensive review is helpful in obtaining a broader picture of this syndrome. The study highlighted the interesting observation that the first symptom in a majority of anti-Jo-1 patients is an extramuscular feature.
32. Brouwer R, Vree Egberts W, Jongen PH, et al.: Frequent occurrence of anti-tRNA(His) autoantibodies that recognize a conformational epitope in sera of patients with myositis. Arthritis Rheum 1998, 41:1428–1437.
33. Hirakata M, Matsuura Y, Suwa A, et al.: Immunological and histopathological features of patients with anti-SRP autoantibodies [abstract]. Arthritis Rheum 1997, 40:S146.
34. Hengstman GJ, van Engelen BG, Vree Egberts WT, van Venrooij WJ: Myositis-specific autoantibodies: overview and recent developments. Curr Opin Rheumatol 2001, 13:476–482.
35. Shamim EA, Rider LG, O’Hanlon TP, et al.: Clinical, serologic and genetic differences between U.S. Caucasians and Meso- Americans with idiopathic inflammatory myopathy (IIM) [abstract]. Arthritis Rheum 1999, 42:S403.
36. Rider LG, Miller FW, Targoff IN, et al.: A broadened spectrum of juvenile myositis: myositis-specific autoantibodies in children. Arthritis Rheum 1994, 37:1534–1538.
37. Seelig HP, Moosbrugger I, Ehrfeld H, et al.: The major dermatomyositis-specific Mi-2 autoantigen is a presumed helicase involved in transcriptional activation. Arthritis Rheum 1995, 38:1389–1399.
38. Ge Q, Nilasena DS, O’Brien CA, et al.: Molecular analysis of a major antigenic region of the 240-kD protein of Mi-2 autoantigen. J Clin Invest 1995, 96:1730–1737.
39. Seelig HP, Renz M, Targoff IN, et al.: Two forms of the major antigenic protein of the dermatomyositis-specific Mi-2 autoantigen. Arthritis Rheum 1996, 39:1769–1771.
40. Woodage T, Basrai MA, Baxevanis AD, et al.: Characterization of the CHD family of proteins. Proc Natl Acad Sci U S A 1997, 94:11472–11477.
41. Zhang Y, LeRoy G, Seelig HP, et al.: The dermatomyositisspecific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities. Cell 1998, 95:279–289.
42. Wang HB, Zhang Y: Mi2, an auto-antigen for dermatomyositis, is an ATP-dependent nucleosome remodeling factor. Nucleic Acids Res 2001, 29:2517–2521. Conclusively establishes a role for Mi-2 antigen in nucleosome remodeling.
43. Zhang Y, Ng HH, Erdjument-Bromage H, et al.: Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev 1999, 13:1924–1935.
44. Marguerie C, Bunn CC, Copier J, et al.: The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl. Medicine 1992, 71:327–336.
45. Ge Q, Wu Y, James JA, Targoff IN: Epitope analysis of the major reactive region of the 100-kd protein of PM-Scl autoantigen. Arthritis Rheum 1996, 39:1588–1595.
46. Bluthner M, Mahler M, Muller DB, et al.: Identification of an alpha-helical epitope region on the PM/Scl-100 autoantigen with structural homology to a region on the heterochromatin p25beta autoantigen using immobilized overlapping synthetic peptides. J Mol Med 2000, 78:47–54. A major epitope of PM-Scl is analyzed in detail, suggesting a relation to another antigen recognized by some patients with scleroderma.
47. Allmang C, Petfalski E, Podtelejnikov A, et al.: The yeast exosome and human PM-Scl are related complexes of 3’ --> 5’ exonucleases. Genes Dev 1999, 13:2148–2158. Establishes the PM-Scl antigen complex as the human homologue of the exosome, a complex of exonucleases involved in ribonucleic-acid processing.
48. Brouwer R, Pruijn GJ, van Venrooij WJ: The human exosome: an autoantigenic complex of exoribonucleases in myositis and scleroderma. Arthritis Res 2001, 3:102–106. Helpful description of the PM-Scl antigen complex.
49. Brouwer R, Allmang C, Raijmakers R, et al.: Three novel components of the human exosome. J Biol Chem 2002, 276:6177–6184. Further characterization of the PM-Scl antigen.
50. Mozaffar T, Pestronk A: Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighbouring muscle fibres. J Neurol Neurosurg Psychiatry 2000, 68:472–478. This careful analysis of muscle histology in anti-Jo-1-positive myositis demonstrated distinctive features that suggest fundamental differences between this condition and antibody-negative myositis.
51. Nagaraju K, Raben N, Loeffler L, et al.: Conditional upregulation of MHC class I in skeletal muscle leads to selfsustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci U S A 2000, 97:9209–9214. Interesting and revealing model that suggests that anti-Jo-1 can appear as a consequence of myositis or of the conditions leading to it, rather than requiring a primary stimulus, such as a virus, directing the immune response to Jo-1 antigen.
52. Casciola-Rosen L, Andrade F, Ulanet D, et al.: Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity. J Exp Med 1999, 190:815–826. Evidence is presented for a hypothesis that might explain the myriad cellular proteins targeted by autoantibodies, with several myositis antibodies highlighted.
53. Casciola-Rosen LA, Pluta AF, Plotz PH, et al.: The DNA mismatch repair enzyme PMS1 is a myositis-specific autoantigen. Arthritis Rheum 2001, 44:389–396. A new autoantibody associated with myositis, that appears relatively myositis-specific at this point. Although found in less than 10% of patients, the frequency is comparable with several established myositis-associated autoantibodies. The observation of antibodies to other proteins of related function is of particular interest.
54. Goel A, Fertig N, Oddis CV, Londino AV: Serum autoantibodies in idiopathic inflammatory myopathy (IIM) of childhood [abstract]. Arthritis Rheum 1996, 39:S191.
55. Oddis CV, Fertig N, Goel A, et al.: Clinical and serological characterization of the anti-MJ antibody in childhood myositis [abstract]. Arthritis Rheum 1997, 40:S139.
56. Targoff IN, Shamim E, Sherry DD, Wallace C, Haftel H, Miller FW, Rider LG, The Childhood Myositis Heterogeneity Study Group, The International Myositis Collaborative Study Group: A novel dermatomyositis (DM)-associated autoantibody directed against a 155 kd protein [abstract]. Arthritis Rheum 2000, 43:S175.
57. Targoff IN, Trieu EP, Sontheimer RD: Autoantibodies to 155 kd and Se antigens in patients with clinically-amyopathic dermatomyositis [abstract]. Arthritis Rheum 2000, 43:S194.
58. Arad-Dann H, Isenberg DA, Shoenfeld Y, et al.: Autoantibodies against a specific nuclear RNP protein in sera of patients with autoimmune rheumatic disease associated with myositis. J Immunol 1987, 138:2463–2468.
59. Arad-Dann H, Isenberg D, Ovadia E, et al.: Autoantibodies against a nuclear 56-kDa protein: a marker for inflammatory muscle disease. J Autoimmun 1989, 2:877–888.
60. Cambridge G, Ovadia E, Isenberg DA, et al.: Juvenile dermatomyositis: serial studies of circulating autoantibodies to a 56kD nuclear protein. Clin Exp Rheumatol 1994, 12:451–457.
61. Lutz JL, Fedczyna TO, Isenberg D, et al.: The association of the DQA1*0501 allele and antibody to a 56 kD nuclear protein in sera from patients with juvenile dermatomyositis (JDM) [abstract]. Arthritis Rheum 2001, 44:S293.
62. Kajihara M, Kuwana M, Tokuda H, et al.: Myositis and interstitial lung disease associated with autoantibody to a transfer RNA-related protein Wa. J Rheumatol 2000, 27:2707–2710.
63. Gelpi C, Sontheimer EJ, Rodriguez-Sanchez JL: Autoantibodies against a serine tRNA-protein complex implicated in cotranslational selenocysteine insertion. Proc Natl Acad Sci U S A 1992, 89:9739–9743.
64. Tormey VJ, Bunn CC, Denton CP, Black CM: Anti-fibrillarin antibodies in systemic sclerosis. Rheumatology 2001, 40:1157–1162. Confirms the observation of Okano et al. (Arthritis Rheum 1992, 35:95-100) that patients with scleroderma and this antibody have an increased frequency of muscle involvement.
65. Frank MB, McCubbin VR, Trieu EP, et al.: The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies. J Autoimmun 1999, 12:137–142.
66. D’Cruz D, Keser G, Khamashta MA, et al.: Antiendothelial cell antibodies in inflammatory myopathies: distribution among clinical and serologic groups and association with interstitial lung disease. J Rheumatol 2000, 27:161–164.
67. Kubo M, Ihn H, Yazawa N, et al.: Prevalence and antigen specificity of anti-histone antibodies in patients with polymyositis/ dermatomyositis. J Invest Dermatol 1999, 112:711–715.
68. Feist E, Dorner T, Kuckelkorn U, et al.: Proteasome alpha-type subunit C9 is a primary target of autoantibodies in sera of patients with myositis and systemic lupus erythematosus. J Exp Med 1996, 184:1313–1318.
69. Feist E, Kuckelkorn U, Dorner T, et al.: Autoantibodies in primary Sjögren’s syndrome are directed against proteasomal subunits of the alpha and beta type. Arthritis Rheum 1999, 42:697–702.
70. Targoff IN, Miller FW, Medsger TA Jr, Oddis CV: Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol 1997, 9:527–535.